[A23-81] Darolutamide (prostate cancer) - Addendum to Commission A23-21
Last updated 21.09.2023
Project no.:
A23-81
Commission:
Commission awarded on 08.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A23-21 | Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-09-21 A G-BA decision was published.